Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Tufts Medical Center
ClinicalTrials.gov Identifier:
NCT01442870
First received: September 21, 2011
Last updated: October 4, 2013
Last verified: October 2013

September 21, 2011
October 4, 2013
September 2011
December 2013   (final data collection date for primary outcome measure)
Incidence of dose limiting toxicity when metformin is added to chemotherapy [ Time Frame: 1 cycle (at least 3 weeks) ] [ Designated as safety issue: Yes ]
The primary endpoint of the study will be to determine whether metformin can be safely added to a chemotherapy regimen that is previously well tolerated. The rate of dose limiting toxicities will be compared.
Same as current
Complete list of historical versions of study NCT01442870 on ClinicalTrials.gov Archive Site
Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 1 cycle (at least 3 weeks) ] [ Designated as safety issue: Yes ]
Secondary endpoints will include assessment of AEs ≥ grade 3 and Serious Adverse Events (SAEs), assessment of safety beyond the first cycle with metformin, and an exploration of metformin-chemotherapy drug interactions.
Same as current
Not Provided
Not Provided
 
Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy
Prospective Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy

Metformin is a drug that is normally used to treat people with diabetes. New research has discovered that metformin may also kill cancer stem cells. These cancer stem cells make up only a small portion of a cancer, but may be responsible for resistance to chemotherapy or for causing recurrence of the cancer. Future studies are envisioned to that test the efficacy of administering metformin with chemotherapy. The purpose of this study is to assess the safety of administering metformin in combination with chemotherapy. Since chemotherapy and cancer itself both cause adverse events by themselves, this study is designed to have a run-in stage as well as a subsequent randomization to metformin or no metformin. The primary endpoint will compare the rate of dose-limiting toxicities between these two arms. After a period of 3 weeks for the primary endpoint comparison, all patients will receive metformin.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Cancer
Drug: Metformin
Metformin
  • Experimental: Metformin
    Metformin
    Intervention: Drug: Metformin
  • No Intervention: No metformin
    No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
105
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically documented cancer; diagnosis of hepatocellular carcinoma may be made by characteristic radiographic and/or AFP findings 33;
  • Intended treatment with, or currently being treated by anti-cancer chemotherapy in the adjuvant or advanced setting;
  • Age 18 to 79;
  • Adequate renal function (serum creatinine levels <1.5 mg/dL [males], <1.4 mg/dL [females]). If a subject does not meet these criteria, but does have an estimated creatinine clearance >= 60 ml/min using the Cockroft-Gault calculation, they will be allowed. The Cockroft-Gault formula is CrCl = (140-age) x weight(kg)÷(Cr x72), where CrCl = estimated creatinine clearance and Cr is plasma creatinine in mg/dL;
  • Adequate hepatic parameters, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN, and alkaline phosphatase levels ≤ 2.5 x ULN;
  • Must anticipate receiving at least 3 cycles (or treatment periods of at least 3-weeks) of chemotherapy;
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

  • Current use of metformin (within 1 week of start of chemotherapy regimen to be assessed);
  • Patients with type 2 diabetes are allowed, however they will be excluded if there is intent to use metformin for treatment of diabetes during the course of the study;
  • Undergoing chemotherapy treatment concurrent with radiation therapy;
  • Undergoing chemotherapy in a neoadjuvant setting prior to potentially curative surgery;
  • Renal disease or renal dysfunction not meeting inclusion criteria;
  • Significant medical conditions such as cardiovascular collapse (shock), acute myocardial infarction, septicemia, acute or chronic metabolic acidosis;
  • History of, or states associated with, lactic acidosis such as shock or pulmonary insufficiency, alcoholism (acute or chronic), conditions associated with hypoxemia and pancreatitis;
  • Severe dehydration;
  • Clinical or laboratory evidence of hepatic disease;
  • Congestive heart failure requiring pharmacologic treatment, or unstable or acute congestive heart failure;
  • Known hypersensitivity to metformin hydrochloride;
  • Pregnant or lactating women (serum pregnancy test will be performed for all women of child-bearing potential);
  • Psychiatric illness or social situation that would limit compliance with study requirements and/or obscure results
Both
18 Years to 79 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01442870
Metformin Anticancer + Chemo
Yes
Tufts Medical Center
Tufts Medical Center
Not Provided
Principal Investigator: Wasif Saif, MD Tufts Medical Center
Tufts Medical Center
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP